Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
110.16
+2.40 (2.23%)
At close: May 12, 2025, 4:00 PM
108.76
-1.40 (-1.27%)
After-hours: May 12, 2025, 7:52 PM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 170.2, with a low estimate of 105 and a high estimate of 216. The average target predicts an increase of 54.50% from the current stock price of 110.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 6 | 7 | 7 |
| Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $180 | Strong Buy | Maintains | $200 → $180 | +63.40% | May 7, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $160 → $165 | Buy | Maintains | $160 → $165 | +49.78% | May 6, 2025 |
| Baird | Baird | Buy Maintains $160 → $162 | Buy | Maintains | $160 → $162 | +47.06% | May 6, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $190 → $193 | Buy | Maintains | $190 → $193 | +75.20% | Apr 29, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +81.55% | Apr 7, 2025 |
Financial Forecast
Revenue This Year
630.68M
from 385.69M
Increased by 63.52%
Revenue Next Year
1.03B
from 630.68M
Increased by 63.32%
EPS This Year
-3.32
from -5.99
EPS Next Year
2.05
from -3.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 720.8M | 1.3B | 2.1B | ||
| Avg | 630.7M | 1.0B | 1.6B | ||
| Low | 547.8M | 764.6M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.9% | 110.9% | 101.2% | ||
| Avg | 63.5% | 63.3% | 50.6% | ||
| Low | 42.0% | 21.2% | 11.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.76 | 7.90 | 17.25 | ||
| Avg | -3.32 | 2.05 | 9.21 | ||
| Low | -4.61 | -3.05 | -0.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 743.2% | ||
| Avg | - | - | 349.9% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.